A Review of Sodium Glucose Co transporter 2 (SGLT2) Inhibitors for Type 2 Diabetes Mellitus

Introduction

The global prevalence of diabetes in all age-groups has risen to nearly 670 million patients, or 9% of the population worldwide [1]. In the United States, 29.1 million (1 out of every 11) Americans have been diagnosed with diabetes and 86 million (1 out of every 3) Americans are living with pre diabetes [2]. Diabetes lowers life expectancy by up to 15 years, increases cardiac risk by two to four-fold, and leads to micro vascular and macro vascular complications including blindness, renal failure and lower limb amputations [3]. Pharmacologic therapy and therapeutic lifestyle changes can effectively manage the disease and prevent or delay the progression of diabetic complications. Hypoglycemia and weight gain are common adverse effects of diabetes medications, and new classes of medications strive to minimize these events. The sodium glucose cotransporter 2 (SGLT2) inhibitors, or “flozins”, have demonstrated modest weight loss and low risk of hypoglycemia when given as monotherapy. Three SGLT2 inhibitors have been approved by the FDA for the treatment of type 2 diabetes mellitus: Canagliflozin (Invokana®, Janssen Pharmaceuticals), Dapagliflozin (Farxiga®, AstraZeneca/Bristol-Myers Squibb), and Empagliflozin (Jardiance®, Boehringer Ingelheim/Lilly).

Pharmacology

SGLT2 inhibitors inhibit the SGLT2 in the proximal nephron, subsequently reducing the reabsorption of filtered glucose. Excretion of glucose in the urine is increased by up to 80g per day [4]. These agents provide modest weight loss as the result of increased loss of urinary glucose and reduction in blood pressure by means of osmotic diuresis effects [5]. An additional advantage of SGLT2 inhibitors is that these agents are effective at all stages of type 2 diabetes mellitus (T2DM) [6,7]. When therapy is advanced to combination basal/bolus insulin regimens, physicians may discontinue agents such as sulfonylureas and GLP-2 receptor agonists [7]. SGLT2 inhibitors can be utilized as adjunctive therapy to improve glucose control and reduce the amount of insulin needed.

Pharmacokinetics

All of the SGLT2 inhibitors are available as an oral tablet formulation. The oral bioavailability of the SGLT2 inhibitors range from 60-78% and achieves maximum concentration 1-2 hours after administration. The elimination half-life of this class of medication ranges from 10.2-13.1 hours and have a once-daily dosing. Drug metabolism is primarily through glucuronidation by the liver and excretion of the drug is mainly by means of the urinary and fecal route. Since the SGLT2 inhibitors reduce the reabsorption of glucose in the kidney and reduce filtration rates, patients with renal impairment will require additional monitoring and/or dose adjustment. Table 1 provides a summary of the pharmacokinetic profile for the SGLT2 inhibitors [8-10].

Adverse event profile

The risk of hypoglycemia is low when a SGLT2 inhibitor is administered as monotherapy. In combination therapy, the SGLT2 drug class may enhance the hypoglycemic effects with insulin and insulin secretagogues such as sulfonylureas. Prescribers should consider lowering the dose of insulin and monitoring for signs and symptoms of hypoglycemia when initiating SGLT2 adjunctive therapy. Genitourinary infections and polyuria were the most commonly reported adverse events and patients presenting with symptoms should be evaluated. Hypotension, dizziness, and dose-related increase in LDL cholesterol have also been reported. Fractures are rare, but have occurred in susceptible patients. Due to the renal mechanism of action of SGLT2 inhibitors, clinicians need to assess renal function as this class of medication is contraindicated in patients with severe renal function including eGFR <30mL/min/1.73m² [2], end-stage renal disease or on dialysis.

Bladder cancer has been reported in patients treated with SGLT2 inhibitors in clinical trials [8-10], but there is insufficient data to determine if these cases were related to the effects of SGLT2 medications. Case reports of ketoacidosis have been identified in post-marketing surveillance, and the American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) have found in their review of these cases that the incidence of ketoacidosis to be infrequent [11]. If ketoacidosis is suspected or if patient is at risk for ketoacidosis, the SGLT2 agent should be discontinued immediately.
Efficacy

SGLT2 inhibitors have demonstrated efficacy and safety in clinical trials for the treatment of patients with T2DM [12-25]. SGLT2 inhibitors as monotherapy or in combination with another anti-diabetic treatment such as metformin or sulfonylurea have demonstrated efficacy in glycemic control with HgA1c reduction of 0.5-1.0%. Large meta-analysis studies of randomized controlled trials of these agents have found favorable effects on glycemic control, weight and blood pressure [26,27]. The efficacy and safety of the SGLT2 inhibitors have not yet been directed compared with each other in the clinical trials. Data is lacking to support use for the treatment of T1DM at this time [28] (Table 2).

Place in therapy

SGLT2 inhibitors have been approved for the treatment of adults with T2DM. The safety and efficacy of SGLT2 inhibitors have not yet been established in the pediatric (<18 years of age) or type 1 diabetes population. These agents are also available in combination with other classes of medications, including Canagliflozin-Metformin (Invokamet®), Dapagliflozin-Metformin (Xigduo XR®), Empagliflozin-Linagliptan (Glyxambi®).

The American Diabetes Association (ADA) guidelines recommend metformin (Glucophage®) as the initial agent for monotherapy due to high efficacy, low hypoglycemic risk, neutral or modest weight loss effects and low costs [8]. The patient is reassessed after three months and if the HbA1c goal has not been achieved with metformin monotherapy, then an additional agent may be initiated. Dual therapy may consist of metformin and an agent from six classes of medications: sulfonyureas, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 inhibitors or insulin (basal). Patient specific factors, patient preferences, medication costs, drug characteristics and HbA1c lowering effects should all be reflected upon when selecting the additional agent.

Doses of medications should be optimized with the consideration of patient’s tolerability of potential dose-dependent side effects before proceeding to the addition of another agent. In conjunction with pharmacotherapy, ADA supports a patient-centered treatment regimen with continuous support for healthy eating, weight control, increased physical activity and diabetes self-management education (DSME). Table 3 provides a comprehensive summary of recommended monitoring.

### Table 1: Pharmacokinetic Profile.

| SGLT-2 Inhibitor     | Bioavailability (Oral) | Tmax   | Elimination Half-Life (T1/2) | Metabolism | Excretion       |
|----------------------|------------------------|--------|------------------------------|------------|-----------------|
| Canagliflozin (Invokana®) | 65%                    | 1 – 2 hours | 10mg: 10.2 hours 300mg: 13.1 hours | Liver: by UGT1A9 and UGT2B4; minor (7) CYP3A4 metabolism | Feces 41.5%, Urine 33% |
| Dapagliflozin (Farxiga®) | 78%                    | 2 hours | 25mg: 13.1 hours 10mg: 12.9 hours | Liver: by UGT1A9; minor CYP-mediated metabolism | Urine 75%, Feces 21% |
| Empagliflozin (Jardiance®) | >60%                   | 1.5 hours | 10mg: 10.2 hours 25mg: 13.1 hours | Liver: by UGT2B7, UGT1A3, UGT1A8, UGT 1A9 | Urine 54.4%, Feces 41.2% |
Table 2: SGLT2 Drug Profile

| Generic Name       | Brand Name | Dosing                                      | Dose Adjustment | Pregnancy Category | HbA1c Reduction | Cost (AWP)           | Special Instructions                  |
|--------------------|------------|---------------------------------------------|----------------|--------------------|-----------------|---------------------|----------------------------------------|
| Canagliflozin      | Invokana®  | Initial dose, 100mg PO daily; may increase to 300mg PO daily | eGFR 45 - 60ml/ min/ 1.73m(2) – max 100mg/day eGFR<45ml/ min/ 1.73m(2) – Avoid use | C                  | 100mg: 0.77% 300mg: 1.03% | 100mg (30): $435.67 300mg (30): $435.67 | Take before first meal of the day.    |
| FDA Approved 2013  |            |                                             |                |                    |                 |                     |                                        |
| Dapagliflozin      | Farxiga®   | Initial dose, 5mg PO daily; may increase to 10mg PO daily | eGFR<60ml/ min/ 1.73m(2) – Avoid use | C                  | 5mg: 0.0% 10mg: 0.9% | 5mg (30): $435.68 10mg (30): $411.53 | Take in the morning, with or without food. |
| FDA Approved 2014  |            |                                             |                |                    |                 |                     |                                        |
| Empagliflozin      | Jardiance® | Initial dose, 10mg PO daily; may increase to 25mg PO daily | eGFR<45ml/ min/ 1.73m(2) – Avoid use | C                  | 10mg: 0.7% 25mg: 0.8% | 10mg (30): $435.66 25mg (30): $435.66 | Take with or without food.            |
| FDA Approved 2014  |            |                                             |                |                    |                 |                     |                                        |
### Table 3: Monitoring Parameters [8].

| Monitoring | ADA Recommendation |
|------------|---------------------|
| HbA1c      | • In patients meeting treatment goals: assess twice a year  
             • In patients with changes in therapy and/or not meeting treatment goals: assess every 3 months or more frequently as clinically warranted |
| Blood Glucose, Self-Monitoring (SMBG) | • Basal or oral agents: clinical judgement of the healthcare professional (insufficient evidence for when to prescribe SMBG)  
                                            • Multiple dose insulin or insulin pump therapy: prior to meals and snacks, occasionally before bedtime, postprandially, before exercise, suspect hypoglycemia, after treatment of hypoglycemic event, prior to critical tasks |
| Blood Pressure | • Assess at each routine visit, unless more frequently as clinically warranted |
| Cholesterol | • Annual lipid panel, unless more frequently as clinically warranted |
| Renal panel | • Assess renal function prior to initiation, then periodically as clinically warranted |
| Lifestyle modifications | • Assess at each routine visit therapeutic lifestyle changes including healthy eating, weight, physical activity |
| Smoking cessation | • Assess tobacco use status at each routine visit |
| Immunizations | • Influenza vaccine: provide annually  
                       • Pneumococcal vaccine:  
                          1. 2 years of age, provide PPSV23  
                          2. 65 years of age and not previously vaccinated, provide PCV13 followed by PPSV23 6-12 months later  
                          3. 65 years of age and previously vaccinated, provide PCV13 (no sooner than 12 months of recent PPSV dose)  
                       • Hepatitis B vaccine:  
                          1.9-59 years of age and not previously vaccinated, provide vaccine  
                          2. ≥ 60 years of age and not previously vaccinated, consider providing vaccine |
| Psychosocial assessment and care | • Assess at each routine visit |
| Foot examination | • Annual comprehensive foot exam  
                       • If ulcers/foot deformities/insensate feet examine, assess at each routine visit  
                       • Daily foot examination by patient |
| Eye examination | • Annual dilated eye examination |

ADA: American Diabetes Association; PPSV23: Pneumococcal Polysaccharide Vaccine 23; PCV13: Pneumococcal Conjugate Vaccine 13.
A Review of Sodium Glucose Co transporter 2 (SGLT2) Inhibitors for Type 2 Diabetes Mellitus

Wong EY (2016) A Review of Sodium Glucose Co transporter 2 (SGLT2) Inhibitors for Type 2 Diabetes Mellitus. Pharm Pharmacol Int J 4(2): 00070. DOI: 10.15406/ppij.2016.04.00070

Summary

The SGLT2 inhibitors are a new class of medications that have expanded the treatment options for T2DM. This class of medications offers adjunctive glycemic control and has favorable drug characteristics including once-daily frequency, oral route of administration, low risk of hypoglycemia and modest weight loss effects. New SGLT2 inhibitors, such as ipragliflozin (Suglat®), tofogliflozin (Apleway®) and luseogliflozin (Lusefi®), are in the pipeline and may offer additional options to help achieve therapeutic goals [29-31].

References

1. United Nations Department of Economic and Social Affairs. World’s population prospects, the 2015 revision.
2. National Center for Chronic Disease Prevention and Health Promotion Centers for Disease Control and Prevention (2014). National Diabetes Statistic Report, Atlanta, Georgia, USA.
3. U.S. Department of Health and Human Services (2014). Healthy People 2020 Topics & Objectives: Diabetes. Washington, USA.
4. Bays H (2013) Sodium glucose co-transporter type 2 inhibitors: Targeting the kidney to improve glycemic control in diabetes mellitus. Diabetes Ther 4(2): 195-220.
5. Tikkkanen I, Narko K, Zeller C, Green A, Saslai A, et al. (2015) Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 38(3): 420-428.
6. Zhang L, Feng Y, List J, Kasichayanula S, Pfister M (2010) Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycemic control and body weight. Diabetes, obesity & metabolism 12(6): 510-516.
7. Standards of Medical Care in Diabetes-2015 (2015). Diabetes Care 38(Suppl1): S1-S93.
8. Product Information: INVOKANA(TM) oral tablets, canagliflozin oral tablets (2014). Janssen Pharmaceuticals, Inc. (per manufacturer). Titusville, USA.
9. Product Information: FARXIGA oral tablets, dapagliflozin oral tablets (2014). Bristol-Myers Squibb Company (per manufacturer). Princeton, USA.
10. Product Information: JARDIANI(R) oral tablets, empagliflozin oral tablets (2014). Boehringer Ingelheim Pharmaceuticals (per manufacturer). Ridgefield, CT, USA.
11. Association of Scientific and Clinical Review (2015) American Association of Clinical Endocrinology and American College of Endocrinology. AACE/ACE Scientific and Clinical Review: Association of SGLT2 Inhibitors and DKA.
12. Stenlof K, Cefalu WT, Kim KA, Alba M, Usiskin K, et al. (2013) Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 15(4): 372-382.
13. Stenlof K, Cefalu WT, Kim KA, Jodar E, Alba M, et al. (2014) Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin 30(2): 163-175.
14. Yale JF, Bakris G, Cariou B, Yue D, David-Neto E, et al. (2013) Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 15(5): 463-473.
15. Lavalle-Gonzalez FJ, Januszewicz A, Davidson J, Tong C, Qiu R, et al. (2013) Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 56(12): 2582-2592.
16. Rosenstock J, Hansen L, Zee P, Yan Li, William Cook, et al. (2015) Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin. Diabetes Care 38(3): 376-383.
17. Henry RR, Murray AV, Marmolejo MH, Henrickson D, Ptaszynska A, et al. (2012) Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 66(5): 446-456.
18. Bailey CJ, Gross JH, Henrickson D, Ishbal N, Mansfield TA et al. (2013) Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 11: 43.
19. Rosenstock J, Vico M, Wei L, Salsali A, List JF (2012) Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 35(7): 1473-1478.
20. Nauck MA, Del Prato S, Meier JF, Durán-García S, Rohwedder K, et al. (2011) Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled non-inferiority trial. Diabetes Care 34(9): 2015-2022.
21. Strojek K, Yoon KH, HRuba V, Elze M, Langkilde AM, et al. (2011) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 13(10): 928-938.
22. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF (2010) Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 33(10): 2217-2224.
23. Widding JP, Norwood P, T’joen C, Bastien A, List JF, et al. (2009) A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 32(9): 1656-1662.
24. Liakos A, Karagiannis T, Athanasiadou E, Saragianni M, Mainou M, et al. (2014) Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 16(10): 984-993.
25. DeFronzo RA, Levin A, Patel S, Liu D, Kaste R, et al. (2015) Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 38(3): 384-393.
26. Liu XY, Zhang N, Chen R, Zhao JG, Yu P (2015) Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years. J Diabetes Complications 29(8):1295-1303.
27. Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, et al. (2013) Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Annals of internal medicine 159(4): 262-274.

28. Chiang JL, Kirkman MS, Laffel LM, Peters AL. (2014) Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care 37(7): 2034-2054.

29. Ohkura T (2015) Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan. World J Diabetes 16(1): 136-144.

30. Kaku K, Watada H, Iwamoto Y, Utsunomiya K, Terauchi Y, et al. (2014) Efficacy and safety of monotherapy with the novel SGLT2 inhibitor in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol 13: 65.

31. Seino Y, Sasaki T, Fukatsu A, Sakai S, Samukawa Y (2014) Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus. Curr Med Res Opin 30(7): 1219-1230.

Citation: Wong EY (2016) A Review of Sodium Glucose Co transporter 2 (SGLT2) Inhibitors for Type 2 Diabetes Mellitus. Pharm Pharmacol Int J 4(2): 00070. DOI: 10.15406/ppij.2016.04.00070